Higher Efficacy of Sequential Therapy with Interferon-alpha and Lamivudine Combination Compared to Lamivudine Monotherapy in HBeAg Positive Chronic Hepatitis B Patients

Sarin, Shiv Kumar; Kumar, Manoj; Kumar, Rakesh; Kazim, Syed Naqui; Guptan, R. C.; Sakhuja, Puja; Sharma, Barjesh Chander

doi:10.1111/j.1572-0241.2005.00247.x

Cited by 48 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biochemical response to lamivudine in this study was reported in 69.4% of the patients that was the highest response rate among similar studies. The biochemical response to lamivudine was 48.14% in Turkey (27), 57% in Brazil (24), and 40.5% in India (26). The biochemical response to the combination of lamivudine and INF-α was 47.7% in India (26).…”

Section: Discussionmentioning

confidence: 94%

“…The biochemical response to lamivudine was 48.14% in Turkey (27), 57% in Brazil (24), and 40.5% in India (26). The biochemical response to the combination of lamivudine and INF-α was 47.7% in India (26). The same as serologic response, the biochemical response to lamivudine was better in the present study in comparison to the similar studies in other countries that might be due to the lower rate of drug resistance in Iran, especially the city of Hamadan.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Response to Various Treatments in the Patients With Chronic Hepatitis B; A Cross-Sectional Study

Mamani¹,

Majzoobi²,

Eini³

et al. 2014

Avicenna J Clin Microbiol Infect

View full text Add to dashboard Cite

Background: Hepatitis B is one of the most common chronic viral infections worldwide, especially in developing countries. The insufficient treatment of the disease increases the risk of cirrhosis and hepatocellular carcinoma, which impose heavy costs to the patient and the society. Different studies evaluated several protocols for the treatment of the disease. Objectives: The aim of this study was to evaluate the response rate of the different treatments in patients with chronic hepatitis B (CHB). Patients and Methods:In a cross-sectional study, 89 patients with CHB who were referred to Infectious Diseases Clinics during 2004 to 2009 were studied. Serological and biochemical outcomes to the different treatments were evaluated. The data were analyzed by SPSS 16. Results: CHB was more frequent in men (74.2%) than women (25.8%). The mean age of the patients was 36 ± 1.36 years. Fifty-three patients (59.6%) had active CHB while 36 (40.4%) were asymptomatic carriers. Serologic and biochemical responses to the treatment were 50% and 69.44%, respectively. However, 50% of the patients with positive HBeAg showed serologic response to the treatment, 37.5% showed HBeAb as well as reduced amounts of HBeAg, and 12.5% just showed reduced amounts of HBeAg. Patients treated by lamivudine showed the highest serologic response rate (75%). Conclusions: Serologic and biochemical response to the different treatments in the patients were better than other similar studies. Besides, it is recommended to begin antiviral therapy against CHB infection with lamivudine.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Response to Various Treatments in the Patients With Chronic Hepatitis B; A Cross-Sectional Study

Mamani¹,

Majzoobi²,

Eini³

et al. 2014

Avicenna J Clin Microbiol Infect

View full text Add to dashboard Cite

show abstract

“…Sarin et al [9] randomly assigned 75 treatment-naïve HBeAg-positive CHB patients to receive lamivudine 100 mg/d (n = 37) for 52 weeks or sequential therapy (n = 38) with lamivudine for 52 weeks with IFN 5 mIU/d for 16 weeks added after the first 8 weeks. This study differed from previous studies in that lamivudine was continued for 52 weeks in the sequential-therapy arm.…”

Section: Hbeag-positive Chronic Hepatitis Bmentioning

confidence: 99%

“…Several trials evaluating the efficacy of combination therapy with lamivudine and standard interferon (IFN) compared with lamivudine monotherapy or IFN monotherapy have yielded different results [1][2][3][4][5][6][7][8][9].…”

Section: Standard Interferon and Lamivudinementioning

confidence: 99%

Dual therapy for chronic hepatitis B virus

Elsiesy¹,

Dieterich

2008

Curr hepatitis rep

View full text Add to dashboard Cite

“…There is some discussion over whether it is better to start LAM and IFN simultaneously or to have a lead in phase with LAM monotherapy. While sequential therapy has been shown to be more effective than LAM monotherapy, simultaneous therapy has some benefits over sequential therapy -although these are not always significant (61)(62)(63)(64).…”

Section: Interferon/nucleos(t)ide Analog Combinationsmentioning

confidence: 99%

Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon

Marcellin

Sung

Piratvisuth

2010

Liver International

View full text Add to dashboard Cite

Since its approval for the treatment of chronic hepatitis B in 1998, lamivudine (LAM) has been used extensively throughout the world, because of its relatively low costs and favourable tolerability. However, clinical trials and cohort studies have demonstrated that a high rate of resistance to this drug develops and, as a result, it is no longer included as a first-line therapy in most current treatment guidelines. Nevertheless, because of its low cost, this drug continues to be used in many countries and the pool of patients who have developed resistance to LAM continues to increase. Thus, there is a clear need to develop coherent management strategies to treat such patients as well as limit the emergence of resistance in the first instance. The purpose of this review is to highlight the need to aim for long-term treatment success while limiting the emergence of drug resistance and its consequences for the future. In addition to add-on/switch strategies with other nucleos(t)ide analogs, currently available data suggest that interferon-based therapies, with their potential to induce a sustained response, are worthy of consideration not only for reducing de novo resistance but as an option for the management of those patients in whom drug resistance has already developed.

show abstract

Higher Efficacy of Sequential Therapy with Interferon-alpha and Lamivudine Combination Compared to Lamivudine Monotherapy in HBeAg Positive Chronic Hepatitis B Patients

Cited by 48 publications

References 18 publications

Response to Various Treatments in the Patients With Chronic Hepatitis B; A Cross-Sectional Study

Response to Various Treatments in the Patients With Chronic Hepatitis B; A Cross-Sectional Study

Dual therapy for chronic hepatitis B virus

Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon

Contact Info

Product

Resources

About